2017-03-003 + 2016-01-001 -GAS-1 : New Treatment Against Neutralizing Antibodies in Gram Negative Infections

GAS-1

2017-03-003 + 2016-01-001

Role of anti-αGal antibodies in nosocomial enteric gram-negative infections of ICU patients. It's feasible boosting the immunity against these pathogens without the need of generating new antibodies. This treatment would positively impact on patient survival and quality of life, reducing the need for clinical intervention and the use of antibiotics, slowing the emergence of multi-drug resistant bacteria.

Bacterial infections Antibody-dependent enhancement (ADE) of bacterial infections occurs when blocking antibodies facilitate the infectivity of pathogens. Natural antibodies against Galα1-3Galβ1-4GlcNAcβ (αGal) epitope act as blocking antibodies against Gram-negative bacteria. This phenomenon contributes to the global and increasing the augment of antimicrobial resistance (AMR).The Intensive Care Unit (ICU) is the worst scenario for AMR. Patients admitted to ICUs are at high risk of acquiring infections, mainly by gram-negative bacteria, because of their underlying illness and constant exposure to invasive practices. RA0127 removes anti-αGal antibodies and is developed to protect ICU patients from Gram-negative bacterial infections.

0

0

0

Bacterial infections at hospitals

Finalize phase I clinical trial with the most advanced product: RA0127

EP14382324.3 (Priority date: 22/08/2014)  WO2016026981

The number of patients admitted to ICU that may benefit from the treatment with RA-01 to prevent the acquirement of Gram-negative infections is more than 4 million per year. We estimate that a treatment cost between $ 600 and $ 1000, which would be cost-benefit for healthcare systems, could generate a peak-year commercial opportunity ranging from $ 1.2 billion to $ 4 billion for the treatment from 2 to 4 million ICU patients. The initial prevention of Gram-negative infections in ICU patients with the use of RA-01 may be later expanded to patients admitted to non-ICU hospital wards with a higher risk for developing nosocomial infections. This includes patients undergoing major surgeries, and having severe immunosuppression or medical comorbidities. RemAb development plan is composed by three different programs. The Program-01 is oriented to prevent Gram-negative nosocomial infections (RA-01).